Enliven Therapeutics, Inc. (ELVN)
27.90
+0.70
(+2.55%)
USD |
NASDAQ |
Jan 22, 11:51
Enliven Therapeutics Enterprise Value: 1.137B for Jan. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Coherus Oncology, Inc. | 60.89M |
| Allogene Therapeutics, Inc. | 192.52M |
| Pyxis Oncology, Inc. | 44.70M |
| CEL-SCI Corp. | 14.39M |
| AIM ImmunoTech, Inc. | 3.371M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.15M |
| Total Expenses (Quarterly) | 20.15M |
| EPS Diluted (Quarterly) | -0.3245 |
| Earnings Yield | -6.62% |
| Normalized Earnings Yield | -6.616 |